HDAC-IN-105

HDAC-IN-105 (Compound 7e) (5-30 μM; 24 h) concentration-dependently reduces total cellular HDAC activity in MDA-MB-231 triple-negative breast cancer cells, with an apparent IC₅₀ of 26.58 μM and a 63% reduction at 30 μM after 24 h of incubation^[1].
HDAC-IN-105 (20-30 μM; 24 h) induces dose-dependent cytotoxic morphological changes in MDA-MB-231 triple-negative breast cancer cells after 24 h of incubation^[1].
HDAC-IN-105 (10-100 μM; 24 h) exhibits potent antiproliferative activity with an IC50 of 27.59 μM in MDA-MB-231 cells, 34.18 μM in MCF-7 cells, 64.21 μM in HUVEC cells, and 105.23 μM in HDF cells^[1].
HDAC-IN-105 (20-30 μM; 24 h) at 30 μM induces G2/M phase cell cycle arrest in MDA-MB-231 triple-negative breast cancer cells after 24 h of incubation, increasing the percentage of cells in G2/M phase from 20.6% to 33.2%^[1].
HDAC-IN-105 (20-30 μM; 24 h) dose-dependently induces apoptosis in MDA-MB-231 triple-negative breast cancer cells after 24 h of incubation, increasing apoptotic cell percentage up to 24.5%^[1].
HDAC-IN-105 (20-30 μM; 24 h) dose-dependently induces loss of mitochondrial membrane potential in MDA-MB-231 triple-negative breast cancer cells after 24 h of incubation, affecting up to 54% of cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.